Deep remission in early relapse 2L DLBCL with COLUMVI + GemOx 56~ durable CR in early relapse 2L DLBCL at 3 years

https://mcj20l77mmv6zbm64ff24smgz911.pub.sfmc-content.com/m2x3t01tdmu?cid=na5589337334&utm_source=medscape&utm_medium=na&utm_campaign=columvi_branded_phase2&utm_content=tx%3Anc3yosdata%3A2512%3Axx&dclid=CjkKEQjw687NBhCM3eyk7NqR_qgBEiQAhPZfllSj2GnUd4bzsCi887ju7qZJJSl31TosJ7ejhjMojAvw_wcB&gad_source=7&gad_campaignid=23190769370 At 3 years, COLUMVI + GemOx continues to deliver a sustained overall survival benefit with a manageable safety profile. As the first and only off‑the‑shelf therapy with curative potential in 2L DLBCL, COLUMVI + GemOx is now recommended by EHA and ESMO Guidelines with the highest category of evidence (I,A).1-6 COLUMVI in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).1 COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.1